This study will use \[18F\]-AraG PET/CT scans to monitor patients who have been diagnosed with locally advanced Head and Neck Squamous Cell carcinoma (LA-HNSCC), and are planning to undergo standard of care chemoradiotherapy for treatment.
Patients ≥18 years of age.
Ability to provide written informed consent and HIPAA authorization.
LA-HNSCC in the larynx, hypopharynx, or human papillomavirus (HPV) negative oropharynx and is planning to receive definitive CRT as the SOC treatment, which includes a total of 70 Gy of radiation dose in 33 fractions, delivered over 5 days a week for 7 weeks, as well as planned weekly cycles of cisplatin (CDDP).
Tumor stage III and IV (AJCC 8th edition).
Diagnosis of immunodeficiency or receiving systemic steroid therapy or any form of immunosuppressive therapy within 7 days prior to the PET/CT scan.
Pregnant or breastfeeding.
Patients that will receive definitive induction chemotherapy or surgery.
Patients who are unable to complete the radiation therapy.
Indiana University
Lead sponsor
CellSight Technologies, Inc.
Collaborator